[A case of hepatocellular carcinoma with liver cirrhosis type C surviving over 2 years by repeated transarterial infusion therapy using cisplatinum].
A 58-year-old man with hepatocellular carcinoma (HCC) with liver cirrhosis type C was admitted to our division in April, 2004 to receive transarterial chemo-embolization (TACE) as a first-line chemotherapy for HCC. Thereafter, he had TACE twice for multicentric HCC. In December, 2005, TACE was thought to have become ineffective since his multicentric HCC progressed. So, we employed transarterial injection therapy (TAI) with fine powder cisplatinum (IAC) as a second-line chemotherapy. Stable disease was accomplished by the 22 sessions of TAI with IAC. After February 2008, IAC was given in combination with degradable starch microspheres (DSM) to reinforce the anti-cancer effect. The total therapeutic sessions using IAC became 26 in number. Total IAC amount used reached to more than 2,200 mg without any serious adverse reaction. In conclusion, TAI using IAC is thought to be effective in the chemotherapy of HCC, safely controlling the tumor progression.
Miura
Tomofumi
T
Division of Gastroenterology and Hepatology, Nagaoka Red Cross Hospital.
Tsuboi
Yasunori
Y
Takano
Toru
T
Ozeki
Yutaka
Y
Nakamura
Junichiro
J
Yamada
Satoshi
S
Miura
Tsutomu
T
Yanagi
Masahiko
M
Takahashi
Toru
T
D006528:Carcinoma, Hepatocellular / Q000150:complications* / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D019698:Hepatitis C, Chronic / Q000150:complications; D006801:Humans; D007261:Infusions, Intra-Arterial; D008103:Liver Cirrhosis / Q000150:complications*; D008113:Liver Neoplasms / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D002945:Cisplatin